Metzner C, Ziesenhenn K, Müller H, Kirsch W D
Z Gesamte Inn Med. 1977 Aug 15;32(16):407-8.
With the help of 5 cases with toxic hepatosis by administration of Gravistat the problems concerning ovulation inhibitor and toxic hepatosis were explained. The clinical, paraclinical and histological findings may be pronounced differently. Anamnestically in prescribing ovulation inhibitors particularly a jaundice during pregnancy or a pronounced pruritus in the 3rd trimester of the pregnancy must be taken into consideration. Toxic liver damage may appear not only when the ovulation inhibitor is given the first time, but also after changing it. For this reasons idiopathic jaundice during pregnancy and condition after toxic hepatosis by ovulation inhibitor in every case must be regarded as contraindications for the application of oral contraceptives. In order to establish subclinical courses a control of transaminases in the first three cycles of using the remedies is to be demanded.
借助5例因服用Gravistat导致中毒性肝病的病例,对排卵抑制剂与中毒性肝病相关问题进行了解释。临床、副临床及组织学表现可能存在差异。在问诊时,开具排卵抑制剂时尤其要考虑到孕期黄疸或妊娠晚期明显瘙痒的情况。中毒性肝损伤不仅可能在首次使用排卵抑制剂时出现,也可能在更换药物后出现。因此,孕期特发性黄疸以及排卵抑制剂导致中毒性肝病后的情况,在任何情况下都必须视为口服避孕药应用的禁忌证。为了发现亚临床病程,在使用药物的前三个周期需要检测转氨酶。